<DOC>
	<DOC>NCT01976650</DOC>
	<brief_summary>This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy of dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant used to treat Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye in clinical practice.</brief_summary>
	<brief_title>Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients with Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or noninfectious uveitis affecting the posterior segment of the eye treated with (OZURDEX®) in clinical practice. Patients with eye infections Patients with glaucoma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>